Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Novartis
MacroGenics
Nurix Therapeutics, Inc.
Xencor, Inc.
Toray Industries, Inc
Theratechnologies
Carisma Therapeutics Inc
Hoffmann-La Roche
Eli Lilly and Company
Instil Bio
Canadian Cancer Trials Group
Xencor, Inc.
MacroGenics
Novartis
Abramson Cancer Center at Penn Medicine
Pfizer
Wake Forest University Health Sciences
University of Louisville
Alliance for Clinical Trials in Oncology
University of Southern California
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
University of Arizona
City of Hope Medical Center
SWOG Cancer Research Network
Indiana University
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center